198 related articles for article (PubMed ID: 23528733)
1. HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A.
Bolduan S; Hubel P; Reif T; Lodermeyer V; Höhne K; Fritz JV; Sauter D; Kirchhoff F; Fackler OT; Schindler M; Schubert U
Virology; 2013 Jun; 440(2):190-203. PubMed ID: 23528733
[TBL] [Abstract][Full Text] [Related]
2. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu.
Shah AH; Sowrirajan B; Davis ZB; Ward JP; Campbell EM; Planelles V; Barker E
Cell Host Microbe; 2010 Nov; 8(5):397-409. PubMed ID: 21075351
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses.
Prévost J; Pickering S; Mumby MJ; Medjahed H; Gendron-Lepage G; Delgado GG; Dirk BS; Dikeakos JD; Stürzel CM; Sauter D; Kirchhoff F; Bibollet-Ruche F; Hahn BH; Dubé M; Kaufmann DE; Neil SJD; Finzi A; Richard J
mBio; 2019 Jun; 10(3):. PubMed ID: 31213558
[TBL] [Abstract][Full Text] [Related]
4. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Vpu Downmodulates ICAM-1 Expression, Resulting in Decreased Killing of Infected CD4
Sugden SM; Pham TNQ; Cohen ÉA
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148794
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction.
Schmidt S; Fritz JV; Bitzegeio J; Fackler OT; Keppler OT
mBio; 2011; 2(3):e00036-11. PubMed ID: 21610122
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin.
Andrew AJ; Miyagi E; Strebel K
J Virol; 2011 Mar; 85(6):2611-9. PubMed ID: 21191020
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Vpu mediated downregulation of CD155 requires alanine residues 10, 14 and 18 of the transmembrane domain.
Bolduan S; Reif T; Schindler M; Schubert U
Virology; 2014 Sep; 464-465():375-384. PubMed ID: 25113908
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
[TBL] [Abstract][Full Text] [Related]
11. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Vpu interference with innate cell-mediated immune mechanisms.
Sandberg JK; Andersson SK; Bächle SM; Nixon DF; Moll M
Curr HIV Res; 2012 Jun; 10(4):327-33. PubMed ID: 22524181
[TBL] [Abstract][Full Text] [Related]
13. Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation.
Arias JF; Iwabu Y; Tokunaga K
Curr HIV Res; 2012 Jun; 10(4):283-91. PubMed ID: 22524176
[TBL] [Abstract][Full Text] [Related]
14. β-TrCP dependency of HIV-1 Vpu-induced downregulation of CD4 and BST-2/tetherin.
Blanchet FP; Mitchell JP; Piguet V
Curr HIV Res; 2012 Jun; 10(4):307-14. PubMed ID: 22524179
[TBL] [Abstract][Full Text] [Related]
15. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity.
Arias JF; Heyer LN; von Bredow B; Weisgrau KL; Moldt B; Burton DR; Rakasz EG; Evans DT
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6425-30. PubMed ID: 24733916
[TBL] [Abstract][Full Text] [Related]
16. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
17. Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity.
Marchitto L; Benlarbi M; Prévost J; Laumaea A; Descôteaux-Dinelle J; Medjahed H; Bourassa C; Gendron-Lepage G; Kirchhoff F; Sauter D; Hahn BH; Finzi A; Richard J
mBio; 2023 Aug; 14(4):e0078923. PubMed ID: 37404017
[TBL] [Abstract][Full Text] [Related]
18. Vpu is the main determinant for tetraspanin downregulation in HIV-1-infected cells.
Lambelé M; Koppensteiner H; Symeonides M; Roy NH; Chan J; Schindler M; Thali M
J Virol; 2015 Mar; 89(6):3247-55. PubMed ID: 25568205
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Nef and Vpu are functionally redundant broad-spectrum modulators of cell surface receptors, including tetraspanins.
Haller C; Müller B; Fritz JV; Lamas-Murua M; Stolp B; Pujol FM; Keppler OT; Fackler OT
J Virol; 2014 Dec; 88(24):14241-57. PubMed ID: 25275127
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
